Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer. - Wikidata - wikimedia - TriplyDB

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

http://www.wikidata.org/entity/Q33420251

about

Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.Efficacy and safety of SOX chemotherapy with or without surgery in AFP-producing advanced gastric cancer.CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer.Optimal management of resected gastric cancer.

P2860

Q33728364-B154B439-1DE1-4A2C-8A3B-6EA2016E7262 Q40141364-43F2762B-EB13-4B40-AF5A-B8E9C10C8B4C Q42353453-6FD18E8B-4112-4888-9079-C52D10BFB859 Q55222865-B85E414A-5A28-4F4C-8DEE-0A11CFEF8C5B Q55359616-B6A88DA0-7EDB-4D2E-A162-B9A3E660097C

P2860

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

http://www.wikidata.org/entity/Q33420251

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@ast

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@en

type

label

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@ast

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@en

prefLabel

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@ast

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@en

P1433

Q33420251-1D36B969-9F87-403E-B9D9-CD8470B321AE

P1476

Q33420251-E0572D92-C65C-4610-97FB-066A22780199

P2093

Q33420251-1924CA13-20A5-44EA-BBA2-9D6B1ED8B91D

Q33420251-195D8D43-AF74-4282-8B76-BD781B8A91DB

Q33420251-352385E4-C858-4765-8254-F6876CAB6D28

Q33420251-52170B91-16B6-4B24-A23E-91B35EB2DA90

Q33420251-6EA39D8F-AD00-4976-AE6E-11B8A1F1281E

Q33420251-90784ECE-DDBA-45BC-87F8-43AF6DA6824F

Q33420251-A15B0DE3-051E-4E6F-A5A7-0B1476FE02EB

Q33420251-BC322272-37A5-4E2F-8146-79F09F290882

Q33420251-EDAFDED6-55DC-4A76-AB35-352DAFF24DFA

P2860

Q33420251-1DE82BAF-81F4-4E0C-98F5-0F1BE5237B58

Q33420251-25496781-64E1-4DD9-88E0-8A084C8D2D22

Q33420251-2FB5D5E1-7203-4C68-ADF0-0505FCF3369F

Q33420251-3A40C509-4956-405D-8546-83780755A52A

Q33420251-3DF04FD8-E40C-4BEF-A2FC-DC1F801CABA9

Q33420251-54EC35B6-5DE5-48D3-B3A4-DF2AEA66403A

Q33420251-56EF0DA8-80F3-40D6-B315-E5C8E8E469E2

Q33420251-577D8419-AE0A-4FE0-93F2-97380F20A110

Q33420251-5DAEBFF6-9245-417A-A8B2-F3554A46412D

Q33420251-5F67ADF9-1659-4FA2-B937-7813761DD8F0

P304

Q33420251-D232F770-EAFC-4689-87AC-344503D04393

P31

Q33420251-DE61CCB9-4E9A-4AE8-BA9B-A1A7E785CD26

P356

Q33420251-DCFEC56A-3FBE-4339-A055-E6482E73D7D8

P433

Q33420251-DA39F768-5713-41FC-9FD5-CD4F0404B618

P478

Q33420251-9A1E170C-5B2F-4732-A16C-744B76C25F63

P577

Q33420251-58FB4839-D6E5-4966-964B-813CC1D6BEC1

P5875

Q33420251-5C304ECE-FBE7-427B-A872-2CD0512BB4DB

P698

Q33420251-BC4313BB-B8A1-4D84-945F-FD9BAFB7D775

P921

Q33420251-6F000DE5-37CC-41B9-A244-0403DC8CF21A

P932

Q33420251-488FFDA0-9A67-4223-BD11-B4026462FBDD

P356

P1433

Oncology Letters

P1476

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.

@en

P2093

Aiping Zhou

http://www.w3.org/2001/XMLSchema#string

Chang Shu

http://www.w3.org/2001/XMLSchema#string

Jianjun Zhao

http://www.w3.org/2001/XMLSchema#string

Jinwan Wang

http://www.w3.org/2001/XMLSchema#string

Lin Yang

http://www.w3.org/2001/XMLSchema#string

Qiong Qin

http://www.w3.org/2001/XMLSchema#string

Songnian Hu

http://www.w3.org/2001/XMLSchema#string

Xinghua Yuan

http://www.w3.org/2001/XMLSchema#string

Yi Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

A phase II trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer.

Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.

Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Gastric cancer--patterns of relapse after surgical resection.

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

P304

1451-1457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2014.2821

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272097642

http://www.w3.org/2001/XMLSchema#string

P698

25663930

http://www.w3.org/2001/XMLSchema#string

P921

P932

4315063

http://www.w3.org/2001/XMLSchema#string